The National Institute of Allergy and Infectious Diseases (NIAID) today announced that it is soliciting applications from U.S. and overseas research institutions seeking to become Clinical Trials Units (CTUs) in the Institute's revamped HIV/AIDS Clinical Trials Networks. NIAID, part of the U.S. National Institutes of Health (NIH), supports the world's largest portfolio of clinical research in HIV/AIDS prevention, vaccine and treatment research and development.
This solicitation, the second of two Requests for Applications (RFAs), is designed to increase the efficiency, accountability and integration of NIAID's HIV/AIDS clinical research networks and enhance their capacity to effectively conduct vital clinical research, especially in resource-limited settings.
The first solicitation, "Leadership for HIV/AIDS Clinical Trials Networks," was released in November 2004. The networks emerging from that RFA will focus on developing and evaluating treatments, prevention strategies and vaccines, with an emphasis on interventions that can be employed in resource-limited settings. The Clinical Trials Units funded in response to this RFA will carry out the research agendas of those networks in one or more of the following six priority areas of investigation:
Developing HIV vaccines
Translating research insights into therapies to treat HIV disease
Optimizing clinical management of HIV/AIDS, including co-infections and other HIV-related conditions
Developing microbicides to prevent HIV acquisition and/or transmission
Preventing mother-to-child transmission of HIV
Developing other methods of HIV prevention
"These Clinical Trials Units will help coordinate and carry out the next generation of AIDS research in the United States and globally," says NIAID Director Anthony S. Fauci, M.D. "Our goal is to develop the best possible leadership and research infrastructure to carry out a flexible, collaborative and c
'"/>
Contact: NIAID News Office
niaidnews@niaid.nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases 15-Feb-2005Page: 1 2 3 Related medicine news :1.
NIAID initiates trial of experimental avian flu vaccine2.
NIAID begins enrolling volunteers for novel HIV vaccine study3.
NIAID-sponsored clinical trial aims to boost flu vaccine supply4.
NIAID seeks applicants to lead revamped HIV/AIDS clinical trials networks5.
NIAID launches influenza genome sequencing project6.
NIAID launches program to improve medical tools against emerging infectious diseases7.
NIAID forms network to tackle potentially fatal reaction to smallpox vaccine8.
NIAID rotavirus vaccine licensed for commercialization9.
Second NIAID SARS vaccine candidate helps mice fend off SARS10.
NIAID vaccine protects against SARS virus infection in mice11.
NIAID Ebola vaccine enters human trial